| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Celltrion Inc (KO: 068270)
068270 Technical Analysis
5
| As on 11th Jul 2023 068270 STOCK Price closed @ 146600.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 172800.44 & Strong Sell for SHORT-TERM with Stoploss of 165500.00 we also expect STOCK to react on Following IMPORTANT LEVELS. |
068270STOCK Price
| Open | 148300.00 | Change | Price | % |
| High | 149200.00 | 1 Day | -1700.00 | -1.15 |
| Low | 144000.00 | 1 Week | -6300.00 | -4.12 |
| Close | 146600.00 | 1 Month | -26500.00 | -15.31 |
| Volume | 820156 | 1 Year | -24400.00 | -14.27 |
| 52 Week High 212500.00 | 52 Week Low 141000.00 | ||||
KO Korea Most Active Stocks
| 001470 | 4730.00 | -4.25% |
| 001470 | 4730.00 | -4.25% |
| 010600 | 2780.00 | 29.91% |
| 010600 | 2780.00 | 29.91% |
| 096300 | 156.00 | -6.02% |
| 096300 | 156.00 | -6.02% |
| 011930 | 2655.00 | 3.51% |
| 011930 | 2655.00 | 3.51% |
| 272210 | 17220.00 | 12.99% |
| 272210 | 17220.00 | 12.99% |
KO Korea Top Gainers Stocks
KO Korea Top Losers Stocks
| 068270 Daily Charts |
068270 Intraday Charts |
Whats New @ Bazaartrend |
068270 Free Analysis |
|
|
068270 Important Levels Intraday
| RESISTANCE | 156620.41 |
| RESISTANCE | 153406.80 |
| RESISTANCE | 151420.41 |
| RESISTANCE | 149434.00 |
| SUPPORT | 143766.00 |
| SUPPORT | 141779.59 |
| SUPPORT | 139793.20 |
| SUPPORT | 136579.59 |
068270 Forecast May 2024
| 4th UP Forecast | 222716 |
| 3rd UP Forecast | 198306 |
| 2nd UP Forecast | 183216 |
| 1st UP Forecast | 168128 |
| 1st DOWN Forecast | 125072 |
| 2nd DOWN Forecast | 109984 |
| 3rd DOWN Forecast | 94894.5 |
| 4th DOWN Forecast | 70483.5 |
068270 Weekly Forecast
| 4th UP Forecast | 190921.00 |
| 3rd UP Forecast | 176707.00 |
| 2nd UP Forecast | 167921.00 |
| 1st UP Forecast | 159135.00 |
| 1st DOWN Forecast | 134065.00 |
| 2nd DOWN Forecast | 125279.00 |
| 3rd DOWN Forecast | 116493.00 |
| 4th DOWN Forecast | 102279.00 |
068270 Forecast2024
| 4th UP Forecast | 293052 |
| 3rd UP Forecast | 246084 |
| 2nd UP Forecast | 217052 |
| 1st UP Forecast | 188020 |
| 1st DOWN Forecast | 105180 |
| 2nd DOWN Forecast | 76148 |
| 3rd DOWN Forecast | 47116 |
| 4th DOWN Forecast | 148 |
Celltrion Inc ( KO Korea Symbol : 068270 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
068270 Business Profile
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea. Address: 23 Academy-ro, Incheon, South Korea
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service